Delisting risk
CVKD · NASDAQ · Biotechnology

Cadrenal Therapeutics

Developer of anticoagulation candidates for high-risk hospital and cardiovascular care.

$1.41
Pre-market−0.34 (−19.21%)
At close$1.75(+13.31%)

Something off on this page? Send us feedback.

Next report
Nov 9, 2026
estimated · in 69 days
EPS estimate
−$1.00
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$2.74−$2.09−$1.87−$1.31−$1.41−$1.04−$1.14Pending
Estimate−$1.71−$1.64−$1.60−$1.55−$1.17−$1.51−$1.42−$1.00
Surprise−60.2%−27.4%−16.9%+15.5%−20.5%+31.1%+19.7%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.1KPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$1.00
Aug 2026−$1.42−$1.14+19.7%
May 2026−$1.51−$1.04+31.1%
Mar 2026−$1.17−$1.41−20.5%
Nov 2025−$1.55−$1.31+15.5%

The latest year is open to everyone — the 14 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Sep 2022
Jun 2022
Mar 2022
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 9, 2026−$1.00
Aug 13, 2026−$1.42−$1.14+19.7%+0.5%
May 7, 2026−$1.51−$1.04+31.1%+1.2%
Mar 31, 2026−$1.17−$1.41−20.5%−4.3%
Nov 10, 2025−$1.55−$1.31+15.5%+5.0%

The latest year is open to everyone — the 14 quarters behind it read with an account.

Sign in
Aug 11, 2025
May 8, 2025
Mar 13, 2025
Nov 7, 2024
Aug 7, 2024
May 9, 2024
Mar 11, 2024
Nov 9, 2023
Aug 10, 2023
May 10, 2023
Mar 30, 2023
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022